ArticleBMC infectious diseases2015
Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Available evidence of antibiotic resistance from extended-spectrum β-lactamase-producing Enterobacteriaceae in paediatric patients in 20 countries: a systematic review and meta-analysis.Bulletin of the World Health Organization · 2019Pooled it
- Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial.BMC research notes · 2024Trial
- Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.BMC infectious diseases · 2017Trial
- Clinical impacts and management of urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a narrative review.Childhood kidney diseases · 2025Review
- Piperacillin-Tazobactam versus Cefotaxime as Empiric Treatment for Febrile Urinary Tract Infection in Hospitalized Children.Infection & chemotherapy · 2024Article
- A Five-Year Analysis of Antibiotic Resistance Trends among Bacteria Identified in Positive Urine Samples in a Tertiary Care Hospital from Bucharest, Romania.Antibiotics (Basel, Switzerland) · 2024Article
- The Influence of Non-E. Coli or Extended-Spectrum β-Lactamase-Producing Bacterial Growth on the Follow-Up Procedure of Infants with the First Febrile Urinary Tract Infection.Indian journal of pediatrics · 2023Article
- Management of Pediatric Urinary Tract Infections: A Delphi Study.Antibiotics (Basel, Switzerland) · 2022Article
- The change of antibiotic susceptibility in febrile urinary tract infection in childhood and adolescence during the last decade.Investigative and clinical urology · 2022Article
- Coexistence of aminoglycoside resistance genes in CTX-M-producing isolates ofIranian journal of microbiology · 2021Article
- Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children.Acta paediatrica (Oslo, Norway : 1992) · 2020Review
- Nitrofurantoin Combined With Amikacin: A Promising Alternative Strategy for Combating MDR UropathogenicFrontiers in cellular and infection microbiology · 2020Article
- Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children.Pediatric nephrology (Berlin, Germany) · 2019Article
- Risk factors for gentamicin-resistant E. coli in children with community-acquired urinary tract infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
- Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.Clinical and experimental nephrology · 2019Article
- Aminoglycosides-alive and well in treatment of pediatric infections: A case of benefit versus risk.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2019Article
- Failure of Ciprofloxacin Therapy in the Treatment of Community-Acquired Acute Pyelonephritis caused byInfection & chemotherapy · 2018Article
- Differentiating Kawasaki disease from urinary tract infection in febrile children with pyuria and C-reactive protein elevation.Italian journal of pediatrics · 2018Article
- Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.Paediatric drugs · 2018Article
- Antimicrobial Pharmacotherapy Management of Urinary Tract Infections in Pediatric Patients.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rate of urinary tract infections (UTIs) due to extended-spectrum β-lactamase (ESBL)-producing bacterial strains requiring carbapenem therapy has been increasing in children. This study was conducted to evaluate the effect of non-carbapenem antibiotic therapy on childhood UTIs caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
methodsMedical records of children diagnosed with febrile UTIs due to E. coli or K. pneumoniae between 2010 and 2014 were retrospectively reviewed. The enrolled children were divided into two groups: the ESBL group and the non-ESBL group. Clinical characteristics and therapeutic responses were compared between the two groups.
resultsA total of 211 episodes of UTI (204 caused by E. coli; seven caused by K. pneumoniae) were identified in 205 children. Twenty-two (10.4 %) episodes were categorized into the ESBL group. There was no significant difference in the type of antibiotic administered between the two groups. No carbapenems were administered; however, aminoglycosides were administered for 79.1 % of the total episodes. Although empirical antibiotics were appropriate for more episodes in the non-ESBL group compared with the ESBL group (100.0 % vs. 90.9 %, p = 0.011), there were no significant differences in the frequency of defervescence, bacterial eradication from the urine, acute pyelonephritis and vesicoureteral reflux or fever duration between the two groups.
conclusionsNon-carbapenem antibiotics showed favourable therapeutic effects on childhood UTIs caused by ESBL-producing strains. Aminoglycosides can be an alternative to carbapenems in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.